Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 608 matching trials from the live ClinicalTrials.gov search.
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV), Routine paediatric vaccine - Hepatitis A
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
78
States / cities
Birmingham, Alabama • Dothan, Alabama • Pinson, Alabama + 68 more
Terminated Phase 3 Interventional Accepts healthy volunteers

Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes

NCT00958139
Conditions
Lyme Disease
Interventions
Permethrin, Placebo
Other
Lead sponsor
University of Minnesota
Other
Eligibility
14 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Rice Lake, Wisconsin
Conditions
Meningitis, Meningococcemia, Neisseria Meningitidis
Interventions
A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
3 Years to 5 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
8
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Woburn, Massachusetts + 5 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Evaluation of a Q-fever Vaccine, NDBR 105

NCT00584454
Conditions
Q Fever
Interventions
Q Fever Vaccine (NDBR 105
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
17 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Fort Deterick, Maryland
Conditions
Sepsis
Interventions
Intravenous GR270773- Phospholipid Emulsion, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
132
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 110 more
Conditions
Sexually Transmitted Diseases, Gonorrhea, Chlamydia
Interventions
EVO100, Placebo
Drug
Lead sponsor
Evofem Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,892 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 71 more
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Bardstown, Kentucky • Woburn, Massachusetts • Niles, Michigan + 1 more
Conditions
Infections, Meningococcal
Interventions
rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo, MenABCWY-1, MenABCWY-2, MenABCWY-3
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 25 Years
Enrollment
3,657 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
64
States / cities
Chandler, Arizona • Glendale, Arizona • Jonesboro, Arkansas + 51 more
Conditions
Meningitis, Meningococcal Infection
Interventions
Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Rotavirus Vaccine, Hepatitis B Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 365 Days
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
25
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014), PedvaxHIB, Prevnar, M-M-R II, Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
4,021 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
55
States / cities
Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 45 more
Completed Phase 2 Interventional Accepts healthy volunteers

Online HIV Prevention for Young Male Couples

NCT03284541
Conditions
Hiv, Chlamydia, Gonorrhea
Interventions
2GETHER, Existing Public Health Practice
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Infections, Meningococcal
Interventions
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 50 Years
Enrollment
1,440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
12
States / cities
Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more
Conditions
Bacteremia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Camden, New Jersey
Conditions
Infection, E Coli Infections, Klebsiella Infections, Proteus Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Enterobacterial Infections, Oncologic Disease, Inflammatory Disease, Invasive Fungal Infections
Interventions
18F-FDS PET/CT
Combination Product
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Chronic Fatigue Syndrome
Interventions
Cardiopulmonary Exercise Test (CPET)
Behavioral
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cystic Fibrosis
Interventions
Piperacillin-tazobactam combination product
Drug
Lead sponsor
West Virginia University
Other
Eligibility
8 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Trachoma
Interventions
community surveillance and re-treatment
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Months to 7 Years
Enrollment
2,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Post-Treatment Lyme Disease
Interventions
taVNS
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation of the ID NOW™ CT/NG Test

NCT06395675
Conditions
Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Asymptomatic Condition
Interventions
ID NOW™
Diagnostic Test
Lead sponsor
Abbott Rapid Dx
Industry
Eligibility
14 Years and older
Enrollment
7,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Haemophilus Influenzae Type B Infection
Interventions
Vaxelis, PedvaxHIB
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
6 Weeks to 12 Weeks
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
5
States / cities
Anchorage, Alaska • Chinle, Arizona • Fort Defiance, Arizona + 2 more
Completed Phase 3 Interventional Results available

Bacterial Vaginosis Home Screening to Prevent STDs

NCT00667368
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years to 25 Years · Female only
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 3 more
Conditions
Uncomplicated Urogenital Gonorrhea
Interventions
solithromycin, ceftriaxone, azithromycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Baltimore, Maryland • Cleveland, Ohio • Toledo, Ohio
Conditions
Lyme Disease
Interventions
Lyme Disease Xenodiagnosis
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
New Haven, Connecticut • Bethesda, Maryland • Boston, Massachusetts